Key facts
- Mendra’s last known valuation is $128.0M (Jan 2026).
- It has raised $82.0M; the latest was Early Stage VC ($82.0M) in Jan 2026.
- Notable investors include 8VC, Lux Capital, OrbiMed, Wing Venture Capital, 5AM Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mendra
- ·The full record, as it builds
Funding rounds
No funding rounds for Mendra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mendra
Operator of an AI-native biopharmaceutical company intended to modernize the development and commercialization of rare disease therapies, accelerating access to life-saving treatments for underserved patients worldwide. The company's AI-driven platform integrates deep rare disease expertise with advanced capabilities in asset selection, patient identification, clinical trial enrollment and global commercialization, enabling customers to benefit from faster timelines, improved execution and expanded access to breakthrough therapies.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 4
- Website
- mendra.com/
- Ownership
- Privately Held (backing)
Mendra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mendra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mendra in its N-PORT filings yet. We sweep new filings monthly.